Table 4. Mortality HRs (95% CIs) by region with reference to Europe.
| North America | South and Southeast Asia | South America and the Caribbean | Sub-Saharan Africa |
|---|---|---|---|
| 1. Crude mortality HR compared to Europe (N = 38,187) | |||
| 1.70 (0.87–3.31) | 3.21 (2.03–5.07) | 6.07 (3.87–9.50) | 4.35 (3.02–6.28) |
| 2. Adjusted for complete baseline characteristicsa (N = 38,187) | |||
| 2.03 (1.02–4.02) | 2.96 (1.79–4.88) | 5.94 (3.77–9.38) | 3.37 (2.17–5.23) |
| 3. Adjusted for complete baseline characteristicsa with IPW (N = 38,187) | |||
| 2.52 (1.24–5.11) | 2.78 (1.75–4.42) | 5.61 (3.58–8.77) | 3.23 (2.21–4.73) |
| 4. Adjusted for baseline characteristicsa, including CD4 percent, using complete cases only (N = 13,699) | |||
| 1.84 (0.58–5.81) | 1.90 (0.73–4.91) | 4.20 (1.72–10.29) | 4.09 (1.84–9.13) |
| 5. Adjusted for baseline characteristicsa, including CD4 percent, with imputation for missing CD4 (N = 38,187) | |||
| 2.34 (1.19–4.71) | 1.87 (1.12–3.13) | 5.00 (3.17–7.90) | 2.70 (1.75–4.19) |
| 6. Adjusted for baseline characteristicsa, including CD4 percent, with restricted imputationb (N = 33,126) | |||
| 1.97 (0.97–4.02) | 1.56 (0.91–2.67) | 4.16 (2.54–6.80) | 2.42 (1.51–3.87) |
| 7. Adjusted for baseline characteristicsa, including CD4 count, using complete cases only (N = 19,979) | |||
| 2.18 (0.71–6.66) | 3.16 (1.44–6.96) | 5.52 (2.62–11.67) | 4.57 (2.23–9.35) |
| 8. Adjusted for baseline characteristicsa, including CD4 count, with imputation (N = 38,187) | |||
| 2.37 (1.19–4.71) | 2.40 (1.45–3.96) | 5.49 (3.48–8.65) | 3.01 (1.95–4.67) |
| 9. Adjusted for baseline characteristicsa, including CD4 count, with restricted imputationb (N = 33,126) | |||
| 2.02 (0.99–4.11) | 2.05 (1.20–3.49) | 4.67 (2.86–7.63) | 2.70 (1.68–4.33) |
| 10. Adjusted for baseline characteristicsa and time-updated CD4 count, with imputation (N = 38,187) | |||
| 2.07 (1.05–4.10) | 4.06 (2.45–6.73) | 5.49 (3.46–8.71) | 3.58 (2.28–5.64) |
| 11. Adjusted for baseline characteristicsa, including CD4 count and HAZ, with imputation (N = 38,187) | |||
| 2.31 (1.16–4.60) | 2.21 (1.33–3.67) | 5.21 (3.29–8.23) | 2.85 (1.83–4.43) |
aSex, birth period (pre-1995, 1995–1999, 2000–2005), age at first visit, antiretroviral therapy (never started, started on dual therapy before 2000, started on triple therapy).
bMultiple imputation for missing CD4 restricted to countries with at least 50 CD4 observations at first visit, or <50% missing CD4 if total country N < 50.
Abbreviations: HAZ, height-for-age-Z-score; HR, hazard ratio; IPW, inverse probability weights.